These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

823 related items for PubMed ID: 12230738

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Parkinson's disease.
    Clarke C, Moore A.
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 6. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G.
    Praxis (Bern 1994); 2005 Oct 19; 94(42):1633-8. PubMed ID: 16277084
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Medical hazards of the internet: gambling in Parkinson's disease.
    Larner AJ.
    Mov Disord; 2006 Oct 19; 21(10):1789. PubMed ID: 16941457
    [No Abstract] [Full Text] [Related]

  • 9. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec 19; 9(50):177-9. PubMed ID: 11475497
    [Abstract] [Full Text] [Related]

  • 10. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T.
    J Neurol; 2002 Sep 19; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [Abstract] [Full Text] [Related]

  • 11. [Parkinson's disease].
    Jean-Luc H.
    Rev Prat; 2005 May 31; 55(10):1129-34. PubMed ID: 16097259
    [No Abstract] [Full Text] [Related]

  • 12. [Hallucinations in Parkinson's disease].
    Moser A, Hagenah J, Kömpf D.
    Nervenarzt; 2003 Apr 31; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [Abstract] [Full Text] [Related]

  • 13. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May 31; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment challenges in early stage Parkinson's disease.
    Tetrud J.
    Neurol Clin; 2004 Oct 31; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract] [Full Text] [Related]

  • 16. Controversies in the treatment of Parkinson's disease.
    Hely MA, Morris JG.
    Curr Opin Neurol; 1996 Aug 31; 9(4):308-13. PubMed ID: 8858190
    [Abstract] [Full Text] [Related]

  • 17. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM, Houeto JL.
    Rev Neurol (Paris); 2002 Jul 31; 158(6-7):744-5. PubMed ID: 12486908
    [Abstract] [Full Text] [Related]

  • 18. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M, Benecke R.
    MMW Fortschr Med; 2005 May 17; 147 Spec No 2():28-31. PubMed ID: 15968869
    [Abstract] [Full Text] [Related]

  • 19. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V.
    Issues Emerg Health Technol; 2008 Feb 17; (112):1-6. PubMed ID: 18354859
    [No Abstract] [Full Text] [Related]

  • 20. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G, Ozekmekçi S, Apaydin H, Delil S, Erginöz E.
    Clin Neurol Neurosurg; 2006 Dec 17; 108(8):726-32. PubMed ID: 16564615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.